We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Explorative Assessment of Biomarkers in Overweight and Obese Subjects

This study is currently recruiting participants.
Verified September 2017 by Profil Institut für Stoffwechselforschung GmbH
Sponsor:
ClinicalTrials.gov Identifier:
NCT01910051
First Posted: July 29, 2013
Last Update Posted: September 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Profil Institut für Stoffwechselforschung GmbH
July 11, 2013
July 29, 2013
September 11, 2017
September 2013
December 2017   (Final data collection date for primary outcome measure)
anthropometric measures and metabolic biomarkers indicative of prediabetes [ Time Frame: Day one ]
One blood sample taken on day 1 of the study
Same as current
Complete list of historical versions of study NCT01910051 on ClinicalTrials.gov Archive Site
intra-subject and inter-subject variability of analyzed biomarkers [ Time Frame: within one month ]
Several circulating markers including the traditionally used fasting serum insulin and fasting plasma glucose as well as an oral glucose tolerance test may serve as indicators of prediabetes. Importantly, these parameters show considerable intra-individual short-term variability. The assessments will therefore be repeated three times within a one month period to determine intra-subject variability of the analyzed parameters under the conditions that apply to the trial site and experimental conditions.
Same as current
the correlation between anthropometric data, medical history, and biomarkers with regard to metabolic risk [ Time Frame: up to 3 years ]
assessment of study data at the end of the study
Same as current
 
Explorative Assessment of Biomarkers in Overweight and Obese Subjects
Explorative Assessment of Biomarkers Indicative of Insulin Resistance and Prediabetes in Overweight and Obese Subjects
The rationale for this trial is to apply a simple and minimally strenuous pre-screening approach prior to performing more extensive trial-specific screening and baseline-characterization activities in the resulting pre-selected population of subjects.
The pre-screening assessments are designed to characterize the metabolic risk profile / prediabetic status in an unselected population of overweight and obese volunteers, aiming to pre-select high risk and prediabetic subjects as a target population who may specifically profit from primary diabetes intervention (prevention) strategies.
Observational
Observational Model: Case-Control
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Blood samples
Probability Sample
Generally healthy or Type 2 Diabetes mellitus
Prediabetes
Not Provided
  • Generally healthy
    Generally healthy
  • Type 2 diabetes mellitus
    Type 2 diabetes mellitus
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
600
December 2017
December 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Obese and overweight subjects
  • Considered generally healthy

Exclusion Criteria:

  • Clinically significant acute illness within 2 weeks before study procedures
Sexes Eligible for Study: All
18 Years to 85 Years   (Adult, Senior)
Yes
Contact: Elke Gurschke +4921314018 ext 411 regulatory@profil.com
Germany
 
 
NCT01910051
OBDM-01
No
Not Provided
Not Provided
Profil Institut für Stoffwechselforschung GmbH
Profil Institut für Stoffwechselforschung GmbH
Not Provided
Principal Investigator: Leona Plum-Mörschel, MD Profil Institut für Stoffwechselforschung GmbH
Profil Institut für Stoffwechselforschung GmbH
September 2017
To Top